Lundbeck publishes the results from our research and clinical trials in scientific journals and presents these results at scientific conferences. Lundbeck also discloses clinical trial information and results summaries in public registries and shares clinical data. The Lundbeck policy for scientific publications and responsible clinical trial data sharing covers all scientific publications authored by Lundbeck and clinical trial data sharing for trials sponsored by H. Lundbeck A/S.
Lundbeck publishes the results from clinical trials of its products and drug development candidates, irrespective of whether the results are positive or negative, and acknowledges a special obligation to publish data related to patient safety.
Per current Good Publication Practice, Lundbeck will submit for publication the results of Lundbeck-sponsored clinical trials, primarily in peer-reviewed journals, or as abstracts, posters, or other presentations at scientific meetings. Lundbeck will publish through open access journals whenever possible.
Publication activities will be undertaken responsibly and ethically to ensure that all relevant information is communicated clearly and in a timely manner. Wherever possible, manuscripts will be submitted no later than 18 months after trial completion for approved products. The commitment to publish also applies to drug development compounds for which development has been discontinued. In situations when the data are of limited scientific or clinical value, or in the case of multiple journal rejections, posting results on a public clinical trial registry site may be an option for disclosure.
Lundbeck encourages publication of the results from drug discovery. The timing of nonclinical publications will take into consideration intellectual property rights as well as legislation and national practices in patent law.
When entering into research and development collaborations, it is Lundbeck’s commitment to maintain ethical and transparent publication practices, which is in accordance with Good Publication Practice.
Lundbeck will prepare clinical publications in accordance with the guidelines established by the International Committee of Medical Journal Editors (ICMJE).
To protect intellectual property rights, any collaboration between Lundbeck and a third party will be subject to a formal agreement that will address ownership of and access to data. All authors of a Lundbeck-sponsored publication will be provided with a copy of the final protocol, statistical analysis plan, and clinical trial report, including the statistical tables and figures that are needed to prepare the planned
publication and, on request, will be provided access to the clinical study data.
Lundbeck is committed to ensuring that authorship for all publications complies with the criteria developed by the ICMJE. Lundbeck bases authorship credit on the following criteria:
Lundbeck may employ professional writers to assist in producing publications and presentations. Care will be taken to ensure any such assistance follows ethically acceptable practice by ensuring that:
Lundbeck supports the need for all authors of publications to disclose any potential conflicts of interest, including any financial relationships that might be perceived to bias their work.
Authors are not paid for authorship, but material support, for example professional medical writing assistance may be offered.
Lundbeck is committed to responsible sharing of clinical trial data in a manner that is consistent with: safeguarding the privacy of patients, respecting the integrity of national regulatory systems and protecting the intellectual property of the sponsor.
As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important aspect of advancing research and thereby supporting our purpose of restoring brain health for the future benefit of patients. Lundbeck is committed to sharing clinical trial data from products approved in Europe and/or the United States after 1 January 2014. Requests for other clinical trial data are assessed on a case-by-case basis.
All data requests from researchers will first be reviewed by Lundbeck for completeness, feasibility, compliance with the trial informed consent form and partner agreements as well as for the ability to anonymize data. Data requests are passed on to the Vivli Independent Scientific Review Board (SRB) for merit scientific review in a next step.
Researchers are responsible for gaining any other approvals that are required for the research (for example, from Ethics Committees, Institutional Review Boards, relevant research institutions or funding bodies).
When the application is approved by the Vivli SRB and a Vivli Data Use Agreement has been signed by Vivli and each data requester’s organization, the requested data will be anonymized (if not done previously) and made available in the secure Vivli research environment. The researcher will by default have access to the anonymized data in the cloud for one year, however, this time can be extended if requested.
The Data Use Agreement stipulates that: ‘data recipients are expected to make the analysis results publicly available in printed form, on the internet, or in a presentation in a learned forum and the recipient shall use reasonable efforts to obtain public disclosure of the analysis results in a peer-reviewed journal’. Any publication must be submitted to Vivli, who will share with all data contributors, at least 30 days prior to submission of publication or public disclosure. All data requests with published or publicly presented results are listed on the Vivli portal.
Lundbeck has developed some of the world’s most widely prescribed therapies.
We pursue our business purpose guided by several pillars and our Code of Conduct.
We strive for Progress in Mind - our multifaceted approach to patients.